Journal
ALLERGY
Volume 76, Issue 3, Pages 853-865Publisher
WILEY
DOI: 10.1111/all.14608
Keywords
Antibodies; Neutralizing [Mesh]; COVID-19 [Supplementary Concept]; COVID-19 diagnostic testing [Supplementary Concept]; Enzyme-Linked Immunosorbent Assay [Mesh]; Severe Acute Respiratory Syndrome Coronavirus 2 [Supplementary Concept]
Categories
Funding
- Research Fund of the Swiss Lung Association, Bern
- Uniscientia foundation
- Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung [179334]
Ask authors/readers for more resources
This study compared the diagnostic accuracy of serological immunoassays targeting different proteins of SARS-CoV-2 and found that ELISAs targeting RBD and S1 protein have high sensitivity and specificity. Additionally, most SARS-CoV-2 positive individuals showed neutralizing activity against the live virus. Further evaluation in studies verifying diagnostic accuracy and protective immunity against SARS-CoV-2 is warranted.
Background Serological immunoassays that can identify protective immunity against SARS-CoV-2 are needed to adapt quarantine measures, assess vaccination responses, and evaluate donor plasma. To date, however, the utility of such immunoassays remains unclear. In a mixed-design evaluation study, we compared the diagnostic accuracy of serological immunoassays that are based on various SARS-CoV-2 proteins and assessed the neutralizing activity of antibodies in patient sera. Methods Consecutive patients admitted with confirmed SARS-CoV-2 infection were prospectively followed alongside medical staff and biobank samples from winter 2018/2019. An in-house enzyme-linked immunosorbent assay utilizing recombinant receptor-binding domain (RBD) of the SARS-CoV-2 spike protein was developed and compared to three commercially available enzyme-linked immunosorbent assays (ELISAs) targeting the nucleoprotein (N), the S1 domain of the spike protein (S1), and a lateral flow immunoassay (LFI) based on full-length spike protein. Neutralization assays with live SARS-CoV-2 were performed. Results One thousand four hundred and seventy-seven individuals were included comprising 112 SARS-CoV-2 positives (defined as a positive real-time PCR result; prevalence 7.6%). IgG seroconversion occurred between day 0 and day 21. While the ELISAs showed sensitivities of 88.4% for RBD, 89.3% for S1, and 72.9% for N protein, the specificity was above 94% for all tests. Out of 54 SARS-CoV-2 positive individuals, 96.3% showed full neutralization of live SARS-CoV-2 at serum dilutions >= 1:16, while none of the 6 SARS-CoV-2-negative sera revealed neutralizing activity. Conclusions ELISAs targeting RBD and S1 protein of SARS-CoV-2 are promising immunoassays which shall be further evaluated in studies verifying diagnostic accuracy and protective immunity against SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available